Q2 EARNINGS: Lombard's first US quarter 'encouraging', Mindray slashes sales guidance
This article was originally published in Clinica
Executive Summary
Lombard Medical Technologies was “a bit light on results” during its first quarter as a US-listed company, noted Jefferies analyst Raj Denhoy. But more positively, “there were very encouraging signs for the commercial ramp of [its flagship product] Aorfix,” the analyst added. Aorfix is indicated for the endovascular treatment of abdominal aortic aneurysms (AAA). It got the go-ahead in the US in February 2013, and is currently the only product approved for use in patients with high-angle aneurysms of up to 90 degrees (who account for 30% of the EVAR market).